Stay updated with breaking news from Accelerate Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Newly Appointed Leader and Key Investments Further Expand Partnerships Program and Accelerate Access to Relationship Marketing SolutionsNASHVILLE, Tenn., Feb. 09, 2023last month and the company's focus
07.06.2022 - Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the Annals of Internal Medicine has published additional data from the Phase 3 MOVe-OUT trial evaluating LAGEVRIO (molnupiravir), an ...
Merck Has Completed Manufacturing of 10 Million Courses of Therapy and Remains on Track to Produce at Least 20 Million Courses in 2022 to Provide Widespread Access to Molnupiravir GloballyKENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and R...
08.02.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that a total of approximately 3.1 million courses of molnupiravir, an investigational oral antiviral COVID-19 medicine, have been ...
/PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the company's strong growth trajectory, including 2021...